{"id":5468,"date":"2022-02-01T09:17:36","date_gmt":"2022-02-01T08:17:36","guid":{"rendered":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/analysguiden-har-genomfort-en-analys-av-stayble-therapeutics-och-initierar-aktieanalysbevakning\/"},"modified":"2022-02-01T09:17:36","modified_gmt":"2022-02-01T08:17:36","slug":"analysguiden-har-genomfort-en-analys-av-stayble-therapeutics-och-initierar-aktieanalysbevakning","status":"publish","type":"cision-feed","link":"https:\/\/staybletherapeutics.com\/sv\/cision-feed\/analysguiden-har-genomfort-en-analys-av-stayble-therapeutics-och-initierar-aktieanalysbevakning\/","title":{"rendered":"Analysguiden har genomf\u00f6rt en analys av Stayble Therapeutics och initierar aktieanalysbevakning"},"content":{"rendered":"<p style=\"text-align:justify;margin-top:12px\"><span><span style=\"font-size:9pt\"><span><span style=\"font-family:arial,helvetica,sans-serif\"><span style=\"color:#3b3838\">\u201d<em>Vi fokuserar p\u00e5 den fortsatta utvecklingen av STA363 f\u00f6r att erbjuda ett effektivt behandlingsalternativ mot diskogen ryggsm\u00e4rta. Samtidigt som vi arbetar vidare med v\u00e5r fas 2b-studie vill vi \u00e4ven passa p\u00e5 att \u00f6ka kunskapen och f\u00f6rst\u00e5elsen om v\u00e5ra ambitioner inom behandling av ryggsm\u00e4rta och ber\u00e4tta om v\u00e5r l\u00e4kemedelskandidat. Som ett led i detta har vi etablerat ett partnerskap med Analysguiden f\u00f6r att ge investerare en b\u00e4ttre f\u00f6rst\u00e5else av Stayble Therapeutics<\/em>,\u201d kommenterar VD Andreas Gerward.<\/span><\/span><\/span><\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Analysguiden har genomf\u00f6rt en uppdragsanalys av Stayble Therapeutics. Hela analysen g\u00e5r att l\u00e4sa p\u00e5 f\u00f6ljande l\u00e4nk: https:\/\/www.aktiespararna.se\/analysguiden\/nyheter\/initieringsanalys-stayble-therapeutics-unik-behandling-diskrelaterad-ryggsmarta<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":[],"_links":{"self":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5468"}],"collection":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed"}],"about":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/types\/cision-feed"}],"replies":[{"embeddable":true,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/comments?post=5468"}],"version-history":[{"count":0,"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/cision-feed\/5468\/revisions"}],"wp:attachment":[{"href":"https:\/\/staybletherapeutics.com\/sv\/wp-json\/wp\/v2\/media?parent=5468"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}